Company profile: PrimeraDx
1.1 - Company Overview
Company description
- Provider of multiplexed infectious disease assays and Scalable Target Amplification Routine technology for simultaneous quantitative measurement of multiple nucleic acid targets. Offers the ICEPlex system combining PCR and capillary electrophoresis, companion diagnostics, a C. difficile assay, ViraQuant for virus quantification, translational medicine research solutions, and pharma quality control.
Products and services
- Companion Diagnostics: Custom-engineered services that assist pharmaceutical companies in architecting, developing, and validating bespoke diagnostic tests to accompany targeted therapies
- ICEPlex System: Clinical-grade platform that integrates PCR and capillary electrophoresis to deliver multiplexed, quantitative analysis of various biomarkers within a single sample for simultaneous measurement
- C. difficile Assay: Laboratory-grade diagnostic test developed on the ICEPlex platform for detection of Clostridium difficile, a common healthcare-associated infection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PrimeraDx
CrestOptics
HQ: Italy
Website
- Description: Provider of advanced fluorescence microscopy systems and modules, including CICERO widefield and spinning disk confocal for inverted/upright setups with wide spectral range and high resolution; X-Light V3 spinning disk confocal enabling dual-camera, high-speed, large FOV imaging; DeepSIM super-resolution module; and VisiView software for integrating and optimizing imaging protocols.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CrestOptics company profile →
Dyadic
HQ: United States
Website
- Description: Provider of microbial protein production platforms and bio-based chemicals. Offers the C1 Platform for developing and manufacturing vaccines, antibodies, and therapeutic proteins for human and animal health; the Dapibus Platform for rapid, large-scale non-pharmaceutical proteins for food and nutrition; recombinant HSA, alpha-lactalbumin, and transferrin; and the DYAI-100 COVID-19 vaccine candidate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dyadic company profile →
Ansh Labs
HQ: United States
Website
- Description: Provider of immunoassays for research and clinical diagnostics, custom immunoassay development (optimization and validation), monoclonal antibodies, and research reagents (antibodies, antigens, proteins), plus animal-specific assays for veterinary diagnostics. Focus areas include reproductive medicine, neurodegenerative disorders, and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ansh Labs company profile →
Collagen Solutions
HQ: United States
Website
- Description: Provider of medical-grade collagen formulations and components for regenerative medicine, medical devices, and in-vitro diagnostics, offering custom collagen engineering, GMP contract manufacturing, and product development. Expertise includes native, soluble, fibrillar, powdered and freeze-dried collagen, tissue-engineered materials (pericardium, bone, tendons), and regulatory compliance to GMP, EDQM, ISO13485, ISO 22442.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Collagen Solutions company profile →
Femtogenix
HQ: United Kingdom
Website
- Description: Provider of next-generation DNA-interactive payload molecules for antibody-drug conjugates, discovered and developed via a platform that combines proprietary computational chemistry techniques with founder know-how from over 50 years of DNA-targeted drug experience. Founded in 2015.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Femtogenix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PrimeraDx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PrimeraDx
2.2 - Growth funds investing in similar companies to PrimeraDx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PrimeraDx
4.2 - Public trading comparable groups for PrimeraDx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →